| Outcome Measures: |
Primary: Cumulative recovery of unchanged drug (Ae), The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate, From the start of administration to 168 hours after administration|Cumulative recovery fraction of unchanged drug (Fe), The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate, From the start of administration to 168 hours after administration|Plasma clearance, The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate, From the start of administration to 168 hours after administration|Cmax, The pharmacokinetic parameters of HSK21542 in plasma, From the start of administration to 168 hours after administration|AUC(0-t), The pharmacokinetic parameters of HSK21542 in plasma, From the start of administration to 168 hours after administration|AUC(0-∞), The pharmacokinetic parameters of HSK21542 in plasma, From the start of administration to 168 hours after administration|Tmax, The pharmacokinetic parameters of HSK21542 in plasma, From the start of administration to 168 hours after administration|t1/2, The pharmacokinetic parameters of HSK21542 in plasma, From the start of administration to 168 hours after administration | Secondary: The main metabolites of HSK21542, The main metabolites of HSK21542 in plasma, urine, feces, and dialysate, From the start of administration to 168 hours after administration|Adverse events (AEs), The incidence and severity of AEs, From after administration to the end of telephone follow-up
|
